Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.
| Revenue (TTM) | $78.09M |
| Gross Profit (TTM) | $18.61M |
| EBITDA | $-20.55M |
| Operating Margin | -52.70% |
| Return on Equity | -68.90% |
| Return on Assets | -12.50% |
| Revenue/Share (TTM) | $0.88 |
| Book Value | $0.48 |
| Price-to-Book | 3.26 |
| Price-to-Sales (TTM) | 2.07 |
| EV/Revenue | 1.904 |
| EV/EBITDA | -10.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 102.10% |
| Shares Outstanding | $107.56M |
| Float | $73.46M |
| % Insiders | 6.26% |
| % Institutions | 68.85% |
Volatility is currently expanding
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2026 on Tuesday, August 11, 2026, following the close of market.
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $1.50 per share. Net proceeds to Codexis from the offering are expected to be approximately $23.1 million after underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on or about July 27, 2026, subject to customary closing conditions. Codexis has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 2,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Codexis. In addition, Codexis intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the size or terms of the offering.
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CDXS and any ticker you trade — then tracks every position and per-strategy win rate.
